Feasibility of MR-guided stereotactic ablative body radiotherapy of lymph node oligometastases

被引：0
作者：
Batumalai, V. [1 ]
Crawford, D. [1 ]
Pagulayan, C. [1 ]
Hogan, L. [1 ]
Jelen, U. [1 ]
Loo, C. [1 ]
Dunkerley, N. [1 ]
Picton, M. [1 ]
Geddes, L. [1 ]
Alvares, S. [1 ]
Sampaio, S. [1 ]
Heinke, M. [1 ]
Twentyman, T. [1 ]
Jameson, M. [1 ]
de Leon, J. [1 ]
机构：
[1] GenesisCare, Radiat Oncol, Sydney, NSW, Australia
来源：
RADIOTHERAPY AND ONCOLOGY | 2022年 / 170卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO-0649
引用
收藏
页码：S584 / S584
页数：1
相关论文
共 50 条
  • [31] Assessment of online adaptive MR-guided stereotactic body radiotherapy of liver cancers
    Padgett, Kyle R.
    Simpson, Garrett
    Asher, David
    Portelance, Lorraine
    Bossart, Elizabeth
    Dogan, Nesrin
    PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, 2020, 77 : 54 - 63
  • [32] Analysis of rectal dose during prostate stereotactic body radiotherapy in MR-guided radiotherapy.
    Sritharan, Kobika
    Dunlop, Alex
    Mitchell, Adam
    Mohajer, Jonathan
    Smith, Gillian
    Tree, Alison
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [33] Impact of magnetic resonance-guided versus conventional radiotherapy workflows on organ at risk doses in stereotactic body radiotherapy for lymph node oligometastases
    Werensteijn-Honingh, Anita M.
    Kroon, Petra S.
    Winkel, Dennis
    van Gaal, J. Carlijn
    Hes, Jochem
    Snoeren, Louk M. W.
    Timmer, Jaleesa K.
    Mout, Christiaan C. P.
    Bol, Gijsbert H.
    Kotte, Alexis N.
    Eppinga, Wietse S. C.
    Intven, Martijn
    Raaymakers, Bas W.
    Jurgenliemk-Schulz, Ina M.
    PHYSICS & IMAGING IN RADIATION ONCOLOGY, 2022, 23 : 66 - 73
  • [34] Pulmonary oligometastases: Metastasectomy or stereotactic ablative radiotherapy?
    Widder, Joachim
    Klinkenberg, Theo J.
    Ubbels, Jan F.
    Wiegman, Erwin M.
    Groen, Harry J. M.
    Langendijk, Johannes A.
    RADIOTHERAPY AND ONCOLOGY, 2013, 107 (03) : 409 - 413
  • [35] CT-guided versus MR-guided radiotherapy: Impact on gastrointestinal sparing in adrenal stereotactic body radiotherapy
    Rodriguez, Lori L.
    Kotecha, Rupesh
    Tom, Martin C.
    Chuong, Michael D.
    Contreras, Jessika A.
    Romaguera, Tino
    Alvarez, Diane
    McCulloch, James
    Herrera, Robert
    Hernandez, Rene J.
    Mercado, Jairo
    Mehta, Minesh P.
    Gutierrez, Alonso N.
    Mittauer, Kathryn E.
    RADIOTHERAPY AND ONCOLOGY, 2022, 166 : 101 - 109
  • [36] Adapting outside the box: Simulation-free MR-guided stereotactic ablative radiotherapy for prostate cancer
    de Leon, Jeremiah
    Jelen, Urszula
    Carr, Madeline
    Crawford, David
    Picton, Maddison
    Tran, Charles
    McKenzie, Laura
    Peng, Valery
    Twentyman, Tania
    Jameson, Michael G.
    Batumalai, Vikneswary
    RADIOTHERAPY AND ONCOLOGY, 2024, 200
  • [37] Feasibility of magnetic resonance-guided stereotactic ablative body radiotherapy of liver cancer
    Picton, M.
    Batumalai, V.
    Crawford, D.
    Pagulayan, C.
    Hogan, L.
    Jelen, U.
    Loo, C.
    Dunkerley, N.
    Geddes, L.
    Sampaio, S.
    Heinke, M.
    Twentyman, T.
    Jameson, M.
    de Leon, J.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S298 - S299
  • [38] Stereotactic body radiotherapy for oligometastases
    Tree, Alison C.
    Khoo, Vincent S.
    Eeles, Rosalind A.
    Ahmed, Merina
    Dearnaley, David P.
    Hawkins, Maria A.
    Huddart, Robert A.
    Nutting, Christopher M.
    Ostler, Peter J.
    van As, Nicholas J.
    LANCET ONCOLOGY, 2013, 14 (01) : E28 - E37
  • [39] Safety of Pembrolizumab Combined with Stereotactic Ablative Body Radiotherapy (SABR) for Pulmonary Oligometastases
    Siva, S.
    Bressel, M.
    Loi, S.
    Sandhu, S.
    Tran, B.
    Mooi, J.
    Lewin, J.
    Azad, A.
    Colyer, D.
    Shaw, M.
    Chander, S.
    Cuff, K.
    Wood, S.
    Lawrentschuk, N.
    Murphy, D.
    Pryor, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S248 - S248
  • [40] Should We be Offering Our Patients With Oligometastases Stereotactic Ablative Body Radiotherapy?
    Ostler, P.
    Hoskin, P.
    Martin, A.
    CLINICAL ONCOLOGY, 2021, 33 (12) : 747 - 748
12345